Skip to main content

Currently Skimming:

Appendix C.3: Department of Energy
Pages 151-156

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 151...
... Examples of projects that the department considered successful are set forth below. Project: Microbial Diversity for Novel Biotechnology Applications Russian and Other Partner Institutes: Institute for Volcanology and Seismology, Russian Academy of Sciences Far-East Branch, Petropavlovsk-KamchatkaCenter for Ecological Research and BioResources Development, Pushchino Durmishidze Institute for Biochemistry and Biotechnology, Tbilisi, Georgia Institute for Microbiology, National Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan U.S.
From page 152...
... In May 2012, NHD initiated quality control and assurance procedures of the Lumtek reagents and Luminometers. If successful, Lumtek plans to sell its products to NHD, and NHD will market them in the United States.
From page 153...
... Project: Antibody-Based Diagnostics and Production for High Consequence Animal Pathogens Russian and Other Partner Institutes: Russian State Diagnostic and Prevention Center for Human and Animal Diseases (DPC) Ivanovsky Virology Institute All-Russia Institute for Animal Health Institute of Experimental and Clinical Veterinary Medicine of the Ukrainian Academy of Agricultural Sciences Gamaleya Institute of Epidemiology and Microbiology Industry Partner: New Horizon Diagnostics (NHD)
From page 154...
... The project yielded four invention disclosures. Project: Anti-Cytokine Antibodies: Immune-Mediated Disease Russian Institutes: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry State Institute of Genetics Institute of Highly Pure Biopreparations Russian Research Center for Molecular Diagnostics and Therapeutics Industry Partner: Advanced Biotherapy Concepts, Inc.
From page 155...
... Investments are profit driven, with profits accruing for both participants. These projects have resulted in diverse commercial successes at impressive rates, including efforts in the fields of radioisotope medical therapy, rapid diagnostics, drug development, crop projection, biodecontamination, vaccine delivery, and wound healing.
From page 156...
... The United States Industry Coalition has identified a few challenges for moving forward with this work, namely adaptation to an evolving Russia and developing viable cost-sharing models. Quantifying and valuing cost-sharing are also challenging.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.